Compass Therapeutics Stock
Compass Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Thomas J. Schuetz
- Employees
- 39
- Market cap
- $155 M
- IPO
- 05/04/2021
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage…
Compass Therapeutics stock: price history
1D
-4.1%
1W
-13.4%
1M
-53.0%
6M
-85.7%
YTD
-84.0%
1Y
-81.0%
2Y
-56.6%
5Y
-73.2%
10Y
–
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~7% weaker price swings than usual
Ask the agents about Compass Therapeutics
Analyst assessment of Compass Therapeutics
PRICE TARGET LOW
US$4.00
CONSENSUS
US$4.67
MEDIAN
US$4.00
PRICE TARGET HIGH
US$6.00
0
STRONG BUY
16
BUY
1
HOLD
0
SELL
0
STRONG SELL
17
TOTAL · Buy
As of: 23/09/2026
Compass Therapeutics stock metrics
P/E
-2.07
P/B
0.97
EV/EBITDA
-1.79
RETURN ON EQUITY
-15.1%
NET MARGIN
0.0%
DEBT/EQUITY
0.06
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
71.5%
FLOAT SHARES
128,740,409
AVG. DAILY VOLUME (30D)
5,916,597
Insider transactions (SEC)
Lerner Neil
Lerner Neil
Lerner Neil
Anderman Jonathan
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -4.1%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Compass Therapeutics stock
What does Compass Therapeutics do?
Compass Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Thomas J. Schuetz, the company employs around 39 people.
The IPO was on 05/04/2021; the stock trades on NASDAQ under the ticker CMPX.
What do analysts say about Compass Therapeutics stock?
17 analysts rate the stock, the consensus is Buy (as of 23/09/2026).
The average price target is US$4.67, ranging from US$4.00 to US$6.00, with a median of US$4.00.
This is an external assessment, not a statement by Market Jury.
When does Compass Therapeutics report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly -7% stronger than usual.
Does Compass Therapeutics pay a dividend?
No, Compass Therapeutics currently does not pay a dividend.
Which stocks are comparable to Compass Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Compass Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Compass Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.